Serotonin: release in the forebrain by stimulation of midbrain raphé.

Electrical stimulation of the midbrain raphé, an area in which neuronal perikarya containing serotonin are aggregated, produces an increase in 5-hydroxyindoleacetic acid and a decrease in serotonin in the forebrain. These changes indicate that serotonin in the brain can be released via a specific neural pathway, namely, the system of axons projecting into the forebrain from serotonin-containing neurons in the midbrain raphé.

Central sites and mechanisms of action of nicotine.

Research conducted in this laboratory over the last ten years has been directed towards determining possible CNS sites and mechanisms by which nicotine is producing its psychopharmacological effects. To accomplish these goals, a drug discrimination paradigm was utilized in which rats were trained to detect nicotine using a two-lever operant procedure. In this situation nicotine acted as a discriminative stimulus (DS) to correct lever responding. In other words rats had to be able to differentiate nicotine's effects from saline in order to obtain a food reinforcement. The ability of nicotine to exert its DS effects appear to be dependent upon a stimulation of central nicotinic-cholinergic receptors which are stereospecific to (-)-nicotine. Interestingly, the nicotine DS could not be mimicked or potentiated by elevating brain acetylcholine levels centrally suggesting that the receptor action was non-cholinergic. Additional studies indicated that nicotine is acting at both reticular formation and hippocampus sites. The hippocampal site of nicotine action also appears to be dependent on a dopamine neuron connection as well.

Speculations on the mechanism of action of hallucinogenic indolealkylamines.

In this review we attempt to develop a fluid theoretical model which is being used as a strategy-base for future experimentation. The first two sections (A and B) describe how we have conducted our research, and present the perspective value of each. This is important because the research strategies developed in these laboratories over the last 5 years combine in vitro and in vivo pharmacological techniques as a means of understanding mechanisms of drug action. Sections C and D attempt to describe how we interpret our data and how we have utilized these data to formulate hypotheses concerning drug mechanisms. The last section of this review sets forth our own ideas on how we believe hallucinogenic agents produce their effects and presents some original data, which we feel, allows us to develop the overall hypotheses presented.

Indolealkylamine and phenalkylamine hallucinogens: a brief overview.

Various indolealkylamine and phenalkylamine derivatives are hallucinogenic in man and/or are behaviorally active in animals. This overview is divided into two parts. The first part attempts to bring together information concerning the activity of indolealkylamines (i.e., tryptamines, alpha-methyltryptamines, N,N-dimethyltryptamines, N-alkyltryptamines, lysergic acid derivatives and beta-carbolines) and phenalkylamines (i.e., phenethylamines, phenylisopropylamines) along with major key references, and with emphasis on those agents not recently reviewed. The latter portion of this overview describes some of the work being conducted in our laboratories in an effort to elucidate the role of the neurotransmitter serotonin in the mechanism of action of various indolealkylamine and phenalkylamine hallucinogens.

Discriminative stimulus properties of MDA analogs.

Rats trained to discriminate (+/-) 2,5-dimethoxy-4-methylphenylisopropylamine (DOM) (1.0 mg/kg) from saline, using a standard two-lever operant task, were challenged with various doses of 3,4-methylenedioxyphenylisopropylamine (MDA) and several related agents. The (+/-)-DOM stimulus generalized to (+/-)-MDA, suggesting that both agents apparently produce similar stimulus cues. Related agents, known to produce effects in man similar to those produced by (+/-)-MDA, also resulted in generalization when administered to the DOM-trained animals, e.g., R(-)-MDA and a methoxylated derivative of (+/-)-MDA, (+/-)-2-OMe-4,5-MDA. DOM stimulus generalization was not observed for S(+)-MDA, the N-monomethyl and alpha-demethyl derivatives of MDA, nor for a metabolite of MDA (i.e., 3-methoxy-4-hydroxyphenylisopropylamine). The results suggest that R(-)- and (+/-)-MDA, as well as (+/-)-2-OMe-4,5-MDA, but not the other derivatives of MDA, are capable of producing behavioral (stimulus) effects common to those produced by the training dose of (+/-)-DOM.

Studies on several 7-substituted N,N-dimethyltryptamines.

Several 7-substituted derivatives of N,N-dimethyltryptamine (DMT) were prepared and evaluated in the rat fundus serotonin receptor assay and in a behavioral (discriminative stimulus) assay in rats. Both 7-Me- and 5-OMe-7-Me-DMT possess a higher pA2, and 5,7-(OMe)2-DMT a lower pA2, than that of DMT itself. Like DMT, all three of these compounds produce behavioral effects in rats which are similar to those of the hallucinogen 5-OMe-DMT. Although 7-ET- and 7-Br-DMT possess a higher serotonin receptor affinity than DMT, neither produce behavioral effects which parallel those of 5-OMe-DMT. In contrast, 6-Me-DMT and its 5-OMe derivative do not interact with the serotonin receptors in a competitive manner and are inactive in the discriminative stimulus assay.

Demethyl analogues of psychoactive methoxyphenalkylamines: synthesis and serotonin receptor affinities.

Mono-O-demethylation of several 2,5-dimethoxyphenalkylamines increases their affinity for the serotonin receptors of the isolated rat fundus preparation. In several instances, demethylation of methoxyphenalkylamines results in compounds which produce an antagonism which is not of a competitive nature. With respect to 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), demethylation of the 2-methoxy group alters affinity in a manner which parallels that observed upon demethylation of 5-methoxy-N,N-dimethyltryptamine. Using a discriminative stimulus paradigm, behavioral studies with rats reveal that the 2-hydroxy analogue, but not the 5-hydroxy analogue, of DOM produces effects (interoceptive cues) similar to those produced by 5-methoxy-N,N-dimethyltryptamine.

Barbitone-induced tolerance to the effects of sedative-hypnotics and related compounds on operant behaviour in the rat.

1 Pretreatment doses of barbitone, pentobarbitone, ethanol, and phenytoin (diphenylhydantoin) in non-tolerant rats produced increases in operant responding at low doses and at higher doses resulted in decreases in responding.2 Daily barbitone injections (100 mg/kg, i.p.) resulted in the development of functional tolerance to both the stimulant and depressant effects of barbitone on responding.3 Barbitone tolerance development did not result in any change in the brain or plasma pharmacokinetics of barbitone.4 Barbitone-tolerant rats were cross-tolerant to the behavioural effects of pentobarbitone, ethanol, and phenytoin. The dose-effect curves for all of these drugs were shifted to the right in tolerant rats, compared to non-tolerant rats.5 Comparison of the brain and plasma levels of these drugs in non-tolerant and tolerant rats provided a means of separating functional cross-tolerance from dispositional cross-tolerance. Barbitone-tolerant rats appeared to be functionally cross-tolerant to ethanol in that there was no change in the brain and blood ethanol levels at times when the degree of behavioural impairment was substantially reduced. In contrast to ethanol, cross-tolerance to phenytoin appeared to be due to a decrease in the brain and plasma levels (dispositional tolerance). Cross-tolerance to pentobarbitone appeared to be comprised of both functional and dispositional cross-tolerance.6 The usefulness of a multidisciplinary approach in the analysis of sedative hypnotic tolerance and cross-tolerance is discussed. It is concluded that without the concurrent determination of both brain and plasma drug levels it would not be possible to distinguish between functional and dispositional tolerance.

A comparison of nicotine and structurally related compounds as discriminative stimuli.

1 Of seven nicotine-like compounds tested as discriminative stimuli in the rat, only 3-pyridyl-methylpyrollidine (3-PMP) generalized to the stimulus effects of nicotine. 2 3-PMP caused equivalent nicotine-like responding at a dose (800 microgram/kg) approximately 4 times that used for the original nicotine discrimination (200 microgram/kg). The ED50 for 3-PMP was about 5 times that for nicotine. 3 Testing of the compounds as possible antagonists of the nicotine-elicited cue were negative. 4 The nicotine-like cue produced by an 800 microgram/kg injection of 3-PMP was effectively blocked by mecamylamine but not by hexamethonium or atropine. Thus, 3-PMP appears to produce generalization to the nicotine cue via action on central nicotinic-cholinoceptors as has been previously reported for the nicotine discriminative stimulus. 5 Mecamylamine blocked the stimulus-effects of 3-PMP (800 microgram/kg) and of nicotine (200 microgram/kg) with an ED50 of 0.32 and 0.20 microgram/kg respectively.

Effects of nicotine on the hypothalamic-pituitary-axis (HPA) and immune function: introduction to the Sixth Nicotine Round Table Satellite, American Society of Addiction Medicine Nicotine Dependence Meeting, November 15, 1997.

This meeting was the sixth consecutive Nicotine Round Table Satellite Meeting which was held in Washington, DC, on 15 November, 1996; previous meetings are presented in Table I. The overall objective of these meetings was to bring together scientists and clinicians as a means of developing a dialogue concerning the basic mechanisms of nicotine action and the effects of nicotine on the whole organism. The specific topic of this meeting was chosen because of the potent effects of nicotine on the hypothalamic-pituitary-axis (HPA), and newer concepts indicating that the immune system and the HPA are connected via a variety of neuroendocrine and neurotransmitter elements. Whereas the HPA appears to play a unique role in adapting to internal and external stressors, the immune system appears to act as a forward scout which provides information important to the HPA. This Satellite Meeting evaluated the effects of nicotine from three points of view: (1) the effects of nicotine on HPA function; (2) the effects of the HPA on the pharmacological effects of nicotine; and (3) the effects of nicotine on immune function. This specific presentation will provide an overview of the findings of the meeting and will discuss several of the overriding issues in this area of nicotine research.

Nicotine-induced tolerance and dependence in rats and mice: studies involving schedule-controlled behavior.

Tolerance to nicotine's disruptive effects on operant responding develops rapidly over a 14-36 day repeated dosing period in both rats and mice. This occurred regardless of whether nicotine was administered pre- or post- to each behavioral exposure. Thus, tolerance development appeared to depend on both behavioral as well as pharmacological mechanisms. It is suggested that the pharmacological mechanism(s) involved in the development of tolerance may be related to an up-regulation of brain area nicotinic receptors. As observed with receptor binding studies, mecamylamine did not appear to attenuate the development of pharmacological tolerance to nicotine (does not attenuate nicotinic receptor up-regulation) even though this cholinergic antagonist will antagonize nicotine's acute behavioral disruptive effects completely. However, the fact that mecamylamine may induce some cross-tolerance to nicotine does complicate our interpretation of these data. The development of nicotine tolerance, in part, appears to depend upon an interaction at some acetylcholine-sensitive nicotinic receptor as evidenced by the ability of physostigmine to induce cross-tolerance to nicotine in both the rat and mouse. These data support the view that nicotine may be inducing its effects via at least two separate nicotinic receptors, one of which may be acetylcholine sensitive. Furthermore, binding data suggest that physostigmine's effects were related to a reduction of available central nicotinic receptor sites. In contrast to what humans experience, the rat does not appear as sensitive to nicotine-induced physical dependence, at least when operant behavior is utilized as the dependent variable used to measure withdrawal signs. Other approaches such as drug discrimination and conditioned avoidance paradigms may provide a better alternative to the evaluation of nicotine-induced dependence. Research utilizing schedule-controlled behavior in the mouse, on the other hand, has provided us with an additional model of a nicotine-induced withdrawal syndrome which may be of value in evaluating mechanisms of nicotine dependence. However, as with all of these findings, much work is needed to confirm and further characterize each model in so far as they may provide us with a reliable and specific measure of nicotine dependence.

Discriminative stimulus properties of arecoline: a new approach for studying central muscarinic receptors.

Rats were trained to discriminate arecoline (1.74 mg/kg) from saline in a milk-reinforced (variable interval 12s) two-lever operant paradigm. The discriminative stimulus (DS) effects of arecoline were antagonized by atropine sulfate, but not by atropine methylnitrate or mecamylamine. In contrast to the effects on discrimination, atropine did not antagonize the response rate suppressant effects of arecoline. The DS effect of arecoline completely generalized to oxotremorine, partially generalized to pilocarpine, and did not generalize to nicotine. These data demonstrate that the DS effect of arecoline depends on central muscarinic receptors.

Generalization of morphine and lysergic acid diethylamide (LSD) stimulus properties to narcotic analgesics.

The present investigation sought to determine whether the stimulus properties of morphine and lysergic acid diethylamide (LSD) would generalize to several narcotic analgesics which vary in their subjective effects. Morphine and saline served as discriminative stimuli for one group of rats in a 2-lever discrimination task. LSD and saline were discriminative stimuli for a second group. Depression of one lever in an operant chamber resulted in reinforcement following the administration of morphine or LSD and the opposite lever was reinforced after saline. After discriminated responding was stable, stimulus generalization tests with narcotic analgesics and antagonists showed that the stimulus properties of morphine generalized to methadone and meperidine, and partially to pentazocine, all of which produce morphine-like subjective effects in humans. Morphine stimulus properties did not generalize to nalorphine or cyclazocine, which produce dissimilar subjective effects. The stimulus properties of LSD generalized partially to cyclazocine, but not to nalorphine. In humans cyclazocine and nalorphine produce a high incidence of psychotomimetic effects, but the subjective effects of cyclazocine are differentiable from those of LSD.

Tolerance to the disruptive effects of arecoline on schedule-controlled behavior.

The roles of dispositional, physiological, and behavioral factors in the development of tolerance to the effects of arecoline on operant behavior were assessed. In Experiment I, rats were trained to press a lever on a variable-interval 15-s schedule for milk reinforcement. Dose-effect relationships were assessed prior to and during chronic arecoline (1.74 mg/kg/day) treatment. After 21 days of arecoline administration prior to each session, the dose-effect relationship for total number of responses did not shift. However, the dose-effect relationship for total number of reinforcers shifted to the right. In Experiment II, rats were trained to respond on a fixed-ratio 20 schedule for milk reinforcement. Dose-effect relationships were assessed prior to and during chronic arecoline (0.87 mg/kg/day) administration. One group of rats received daily injections of arecoline prior to the session and a second group received arecoline injections 30 min after the session. Daily administration of arecoline resulted in a greater shift to the right of the dose-effect relationship for the presession group than it did for the postsession group. These data demonstrate the importance of behavioral factors in the development of tolerance to arecoline.

The development of pharmacological tolerance to the effect of nicotine on schedule-controlled responding in mice.

The effects of nicotine in mice responding on a fixed-ratio schedule for a sweetened milk reinforcer were determined before, during and after daily administration of the drug. During chronic treatment, responding was initially depressed in a group of mice given presession injections of nicotine and gradually returned to prechronic baseline levels. Responding to single doses of nicotine shifted to the right following chronic treatment for animals receiving either presession or postsession chronic injections of 1.2 mg/kg nicotine. Following termination of chronic treatment, both groups lost tolerance to the chronic dose at similar rates. These data indicate that animals given chronic pre- and postsession injections of nicotine develop tolerance to the pharmacological effects of the drug and that behavioral variables do not influence the development of tolerance to nicotine.

Behavioral effects of 5-methoxy-N,N-dimethyltryptamine and dose-dependent antagonism by BC-105.

The discriminative effects of 5-methoxy-N,N-dimethyltryptamine (5-OMeDMT) were studied in rats trained to discriminate 1.5 mg/kg or 3.0 mg/kg 5-OMeDMT from saline. A series of antagonist and generalization tests revealed that (1) antagonism of the 5-OMeDMT stimulus response by the presumed serotonin antagonist BC-105 depended on the dose of 5-OMeDMT, (2) the 5-OMeDMT stimulus generalized to LSD, and (3) like 5-OMeDMT, antagonism of the LSD generalization response by BC-105 depended on the dose of LSD. In a second study, with rats responding under a variable-interval (VI) 15-s schedule of reinforcement, doses of 1.0-3.0 mg/kg 5-OMeDMT significantly decreased response rate. Furthermore, the decrease in responding produced by the administration of 1.5 mg/kg (but not by 3.0 mg/kg) 5-OMeDMT was blocked by BC-105. This dose-dependent antagonism was of particular interest since the 1.5 mg/kg and 3.0 mg/kg dose of 5-O-MeDMT had essentially the same effect on responding when given alone. The results of both studies emphasize the importance of 5-OMeDMT dose in antagonism experiments.

Discriminative stimulus properties of pizotifen maleate (BC105): a putative serotonin antagonist.

Rats were trained to discriminate the putative serotonin (5-HT) antagonist, pizotifen maleate (BC105), from saline using a two-lever drug discrimination paradigm. Pizotifen maleate (6 mg/kg, 14.6 mumol/kg, IP) or saline was administered 55 min prior to the operant training session. The pizotifen discriminative stimulus (DS) had a rapid onset (less than 7 min) and was of long duration. The pizotifen DS was dose dependent. The pizotifen DS did not generalize to the putative 5-HT antagonists, methiothepin, xylamidine, and cinanserin. Partial generalization was observed to methysergide and metergoline, and complete generalization to cyrproheptadine and the phenothiazine antihistamine, promethazine. The pizotifen DS failed to generalize to the antipsychotic chlorpromazine, the ethanolamine antihistamine diphenhydramine, the CNS stimulant, d-amphetamine, and the putative 5-HT agonists, LSD and quipazine. LSD and quipazine failed to antagonize the pizotifen DS. The results of this study suggest that different DS properties are associated with the different putative 5-HT antagonists and that pizotifen and cyproheptadine, in addition to their reported 5-HT antagonist properties, share a common property that is also associated with promethazine, probably involving antihistaminergic activity.

Effects of medial raphe and raphe magnus lesions on the analgesic activity of morphine and methadone.

The effects of lesions of the raphe nuclei on opiate-induced antinociception and brain serotonin (5-HT) levels were investigated. Lesions of the medial raphe nucleus effectively antagonized the analgesic effects of morphine, but not methadone, and lowered brain 5-HT. The decrement in analgesic activity of morphine was reversed by pretreatment with 5-hydroxytryptophan. Lesions of the raphe magnus, a descending 5-HT system, antagonized the analgesic potency of both morphine and methadone. These experiments indicate a differential effect of 5-HT manipulation on opiate-induced analgesia, suggesting a different mechanism of analgesic action for morphine and methadone.

Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities.

A choice between two levers in an operant chamber was used to train 24 rats, under a variable-interval 15 s schedule of sweetened milk reinforcement, to discriminate a hallucinogenic (psychotomimetic) agent, 5-methoxy-N,N-dimethyltryptamine (5-OMe DMT), from saline administration. The 5-OMe DMT stimulus generalized in a dose-related manner to each of 14 tryptamine related analogs. With the exception of one compound, the effective dose for the 5-OMe DMT response correlated highly (r = -0.86) with 5-HT receptor affinity (as determined using an isolated rat fundus preparation).

Evidence that nicotine can acutely desensitize central nicotinic acetylcholinergic receptors.

Current concepts concerning nicotine's CNS mechanism(s) of action suggest that this drug produces its effects via an interaction at nicotinic-cholinergic receptors (nAChRs) sensitive to acetylcholine. In vitro research further suggests that, following its initial agonist effect, this cholinergic drug may also induce a rapid desensitization of the nAChR similar to that of acetylcholine, resulting in termination of its pharmacological effect. Research described in this paper provides evidence of this secondary desensitization process in vivo by demonstrating nicotine's ability to induce acute tolerance in a Discriminative Stimulus (DS) paradigm. The ability of nicotine (400 micrograms/kg, SC) to elicit DS control of behavior in a two-lever operant procedure was significantly reduced via a challenge dose (800 micrograms/kg, SC) of nicotine administered 15-180 min before the training dose. Twenty-three of 52 rats demonstrated this phenomenon. The time to develop acute tolerance varied, providing additional evidence that these effects may be contingent upon individual rat variability. In addition, physostigmine was also observed to induce a similar desensitization in a random population of desensitizing rats. Lastly, there were no differences between desensitizers and non-desensitizers in relation to the ability of mecamylamine (1000 micrograms/kg, SC) to antagonize the DS, while in both populations of rats scopolamine (100 micrograms/kg, SC) failed to antagonize the DS.